284 related articles for article (PubMed ID: 32594218)
41. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
42. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
[No Abstract] [Full Text] [Related]
43. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
45. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J;
PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
Heaney JLJ; Campbell JP; Griffin AE; Birtwistle J; Shemar M; Child JA; Gregory WM; Cairns DA; Morgan G; Jackson G; Drayson MT
Br J Haematol; 2017 Jul; 178(2):220-230. PubMed ID: 28573706
[TBL] [Abstract][Full Text] [Related]
47. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
[TBL] [Abstract][Full Text] [Related]
48. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
[TBL] [Abstract][Full Text] [Related]
49. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
50. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
51. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
52. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
53. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
[TBL] [Abstract][Full Text] [Related]
54. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.
Fan H; Yan W; Li L; Xu J; Liu J; Xu Y; Sui W; Deng S; Du C; Yi S; Zou D; Qiu L; An G
Hematology; 2023 Dec; 28(1):2182156. PubMed ID: 36815749
[TBL] [Abstract][Full Text] [Related]
55. Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System.
Wang Q; Zhang L; Li S; Sun Z; Wu X; Zhao A; Benkert T; Zhou D; Xue H; Jin Z; Li J
Acad Radiol; 2022 Jun; 29(6):e98-e107. PubMed ID: 34452820
[TBL] [Abstract][Full Text] [Related]
56. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
57. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
[TBL] [Abstract][Full Text] [Related]
58. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
59. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
Zhao D; Jiang JQ; Lin L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
[TBL] [Abstract][Full Text] [Related]
60. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients.
Cao Y; Gong Y; Zhou X; Sun C
Hematology; 2023 Dec; 28(1):2208914. PubMed ID: 37145015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]